Form 4: Gabrielle Sulzberger, Eli Lilly & Co Director, Acquires Shares Under Directors' Deferral Plan

Director Gabrielle Sulzberger acquired 5.784 shares of Eli Lilly & Co common stock at $857.2 per share through the Lilly Directors' Deferral Plan.

Summary

• On February 18, 2025, Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 5.784 shares of common stock.
• The acquisition was made under the Lilly Directors' Deferral Plan.
• The price per share was $857.2.
• These shares were deferred in lieu of cash compensation as stock units and will be settled in shares of common stock following Sulzberger's separation from service.
• Following the transaction, Sulzberger beneficially owns 2,545.394 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director acquiring shares, even through a deferral plan, is generally seen as a positive sign of confidence in the company. However, it's a routine transaction.

Positives

• Director's participation in the Directors' Deferral Plan demonstrates confidence in the company's future.

Future Outlook

The acquired shares will be settled in shares of common stock following the reporting person's separation from service.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it signals confidence from a company director.

Key Dates

Keywords

Eli Lilly & Co, Director, Share Acquisition, Directors' Deferral Plan, LLY, Beneficial Ownership, Stock Units, Deferred Compensation